Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

68.24 +0.21 (+0.31%)
Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
77 78 Next >
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans. 
Via Benzinga
Exposures Product Safety
MarketBeat Week in Review – 12/16 - 12/20
Stocks were lower this week after the Federal Reserve confirmed fewer rate cuts in 2025, but Friday's rally suggests hope for a Santa Claus rally remains strong 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off. 
Via The Motley Fool
Why Viking Therapeutics Tumbled by More Than 10% This Week
Via The Motley Fool
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Dow Surges Over 600 Points, Gold Jumps 1.5%
Via Benzinga
Topics Stocks
Exposures US Equities
Wall Street Rallies On Soft Inflation Data, Bonds Rebound, Travel Stocks Surge: What's Driving Markets Friday?
Risk sentiment returned to Wall Street on Friday, revitalized by softer-than-expected November inflation data leading to a strong market rebound following the selloff triggered by the Federal Reserve’s... 
Via Benzinga
Topics Economy
Exposures Interest Rates
What's Going On With Amgen Stock On Friday?
Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers competitive weight loss with less frequent dosing. 
Via Benzinga
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
Via Benzinga
Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss
Novo Nordisk's stock is spiraling downwards, with technical analysis revealing a concerning picture of bearish momentum. Short-term opportunities may arise, but the broader downtrend remains strong. 
Via Benzinga
Dow Up 752 Points, Extending Rebound From Dramatic Losses
The Dow Jones Industrial Average is in rally mode, reversing its premarket losses to jump 752 points after yesterday snapping its 10-day losing streak. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for. 
Via The Motley Fool
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Micron, Vertex, Novo Nordisk and Nike were notable losers on news. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market overreacted. 
Via Benzinga
US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Eli Lilly and Viking Therapeutics jumped on Novo's setback. 
Via Investor's Business Daily
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
Novo Nordisk's REDEFINE 1 trial shows CagriSema delivers significant weight loss and a favorable safety profile in obesity treatment. 
Via Benzinga
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Elon Musk Vs. RFK Jr.: Obesity Crisis Debate Sparks Struggle For Trump's Influence
Debate over tackling U.S. obesity epidemic sparks contrasting views from Trump's orbit: lifestyle changes vs. easier access to weight-loss drugs. 
Via Benzinga
Topics Government
Exposures Political
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List
Compounders now have until late March to wind down their operations, depending on their licensing. 
Via Investor's Business Daily
Exposures Product Safety
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
21% of Warren Buffett's "Secret" Portfolio Is Invested in These 3 ETFs. Are They Great Picks for 2025?
Via The Motley Fool
Topics ETFs
This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer. 
Via The Motley Fool
Lennox To Join S&P 500 Index, Replacing Catalent
Lennox, an AI cooling play, will join the S&P 500 before the open on Dec. 23. Bill Holdings will take its pace in the S&P Midcap 400. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease
New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines Agency calls for European review. 
Via Benzinga
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. 
Via MarketBeat
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.